91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In a recent interview with Citeline, the head of 91黑料's Centre for Biosimilar Drug Development discussed the upcoming patent expirations in oncology biologics, the opportunities, regulatory pathways and challenges this presents for developers and greater treatment access for patients.
-
Advancements in biologic therapies have greatly improved our ability to treat cancer over the last few decades — but are typically very costly. With patent expirations encompassing numerous notable oncology biologics, opportunities for oncology biosimilar development are abundant.
-
The patent cliff for biologic medicines presents an opportunity for developers of biosimilars, but historically there are challenges too. The landscape however is changing, supporting easier paths to market.
-
With the impending patent cliff, the opportunities for companies to create biosimilars is expanding. Read our article in Scrip Asia 100 2025 to learn about the regulatory environment, requirements and challenges in an Asian context.
-
An article by Katya Svoboda and Bob Swann which explores .
